AI-driven drug asset discovery and evaluation platform that scans global sources and runs 50+ in silico models to find and assess preclinical drug candidates.
Convexia scans global databases and unstructured data to surface overlooked preclinical drug candidates, from biotech to abandoned pharma IP. Over 50 custom-tuned models assess binding, toxicity, ADME/PK, immunogenicity, and mechanistic fit, with PhD-level experts validating results before greenlighting assets. The platform also provides commercial ranking, digital twin clinical simulations, and a go/no-go decision framework anchored to historical benchmarks, with a live KOL roundtable for final decisions. Convexia is a product of Convexia.
For people
For agents
Nothing listed yet.